A broadly neuroprotective derivative of curcumin

Journal of Neurochemistry

Volumn 105, Issue 4, 2008, Pages 1336-1345

  Liu, Yuanbin ^a   Dargusch, Richard ^a   Maher, Pamela ^a   Schubert, David ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

Amyloid; Curcumin; Drug; Glutamate; Neuroprotection; Oxytosis; Toxicity

Indexed keywords

CNB 001; CURCUMIN; NEUROPROTECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG INHIBITION; DRUG SYNTHESIS; MOUSE; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

ANIMALS; CELL SURVIVAL; CELLS, CULTURED; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; MICE; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PYRAZOLES; RATS;

EID: 42549169394     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2008.05236.x     Document Type: Article

References (49)

1. Abe K., Takayanagi M. Saito H. (1990) Effects of recombinant human basic FGF and its modified protein CS23 on survival of primary cultured neurons from various regions of fetal rat brain. Jpn. J. Pharmacol. 53, 221 227.
2. Aggarwal B. B., Kumar A. Bharti A. C. (2003) Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 23, 363 398.
3. Aoki H., Takada Y., Kondo S., Sawaya R., Aggarwal B. B. Kondo Y. (2007) Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol. Pharmacol. 72, 29 39.
4. Barten D. M., Meredith J. E. Jr., Zaczek R., Houston J. G. Albright C. F. (2006) Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity. Drugs Res. Dev. 7, 87 97.
5. Behl C., Davis J. B., Lesley R. Schubert D. (1994) Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77, 817 827.
6. Berger C., Schabitz W. R., Wolf M., Mueller H., Sommer C. Schwab S. (2004) Hypothermia and brain-derived neurotrophic factor reduce glutamate synergistically in acute stroke. Exp. Neurol. 185, 305 312.
7. Chen J., Zacharek A., Zhang C., Jiang H., Li Y., Roberts C., Lu M., Kapke A. Chopp M. (2005) Endothelial nitric oxide synthase regulates brain-derived neurotrophic factor expression and neurogenesis after stroke in mice. J. Neurosci. 25, 2366 2375.
8. Cole G. M., Teter B. Frautschy S. A. (2007) Neuroprotective effects of curcumin. Adv. Exp. Med. Biol. 595, 197 212.
9. Corson T. W. Crews C. M. (2007) Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell 130, 769 774.
10. Davis J. B. Maher P. (1994) Protein kinase C activation inhibits glutamate-induced cytotoxicity in a neuronal cell line. Brain Res. 652, 169 173.
11. Frautschy S. A., Hu W., Kim P., Miller S. A., Chu T., Harris-White M. E. Cole G. M. (2001) Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol. Aging 22, 993 1005.
12. Goodman Y., Steiner M. R., Steiner S. M. Mattson M. P. (1994) Nordihydroguaiaretic acid protects hippocampal neurons against amyloid [beta]-peptide toxicity, and attenuates free radical and calcium accumulation. Brain Res. 654, 171 176.
13. Harvey A. L. (1999) Medicines from nature: are natural products still relevant to drug discovery? Trends Pharmacol. Sci. 20, 196 198.
14. Kang J. H., Kondo F. Katayama Y. (2006) Human exposure to bisphenol A. Toxicology 226, 79 89.
15. Keller C., Bruelisauer A., Lemaire M. Enz A. (2002) Brain pharmacokinetics of a nonpeptidic corticotropin-releasing factor receptor antagonist. Drug Metab. Dispos. 30, 173 176.
16. Kim H., Park B. S., Lee K. G., Choi C. Y., Jang S. S., Kim Y. H. Lee S. E. (2005) Effects of naturally occurring compounds on fibril formation and oxidative stress of beta-amyloid. J. Agric. Food Chem. 53, 8537 8541.
17. Koehn F. E. Carter G. T. (2005) The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov. 4, 206 220.
18. Kurozumi K., Nakamura K., Tamiya T. et al. (2005) Mesenchymal stem cells that produce neurotrophic factors reduce ischemic damage in the rat middle cerebral artery occlusion model. Mol Ther. 11, 96 104.
19. LaFerla F. M., Green K. N. Oddo S. (2007) Intracellular amyloid-beta in Alzheimer's disease. Nat. Rev. Neurosci. 8, 499 509.
20. Lansbury P. T. Lashuel H. A. (2006) A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 443, 774 779.
21. van Leyen K., Kim H. Y., Lee S. R., Jin G., Arai K. Lo E. H. (2006) Baicalein and 12/15-Lipoxygenase in the Ischemic Brain. Stroke 37, 3014 3018, 2006 Oct 19; [E-Pub ahead of print].
22. Lim G. P., Chu T., Yang F., Beech W., Frautschy S. A. Cole G. M. (2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 21, 8370 8377.
23. Liu Y. Schubert D. (1998) Steroid hormones block amyloid fibril-induced 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) formazan exocytosis: relationship to neurotoxicity. J. Neurochem. 71, 2322 2329.
24. Liu Y., Peterson D. A. Schubert D. (1998) Amyloid beta peptide alters intracellular vesicle trafficking and cholesterol homeostasis. Proc. Natl Acad. Sci. USA 95, 13266 13271.
25. Maezawa I., Hong H. S., Wu H. C. et al. (2006) A novel tricyclic pyrone compound ameliorates cell death associated with intracellular amyloid-beta oligomeric complexes. J. Neurochem. 98, 57 67.
26. Maher P. (2006) Redox control of neural functions: background, mechanisms and significance. Antioxid. Redox Signal. 8, 1941 1970.
27. Mattson M. P. Cheng A. (2006) Neurohormetic phytochemicals: low-dose toxins that induce adaptive neuronal stress responses. Trends Neurosci. 29, 632 639.
28. McPhie D. L., Lee R. K., Eckman C. B., Olstein D. H., Durham S. P., Yager D., Younkin S. G., Wurtman R. J. Neve R. L. (1997) Neuronal expression of beta-amyloid precursor protein Alzheimer mutations causes intracellular accumulation of a C-terminal fragment containing both the amyloid beta and cytoplasmic domains. J. Biol. Chem. 272, 24743 24746.
29. Molina-Holgado F., Hider R. C., Gaeta A., Williams R. Francis P. (2007) Metals ions and neurodegeneration. Biometals 20, 639 654.
30. Olney J. W. (1986) Inciting excitotoxic cytocide among central neurons, in Advances in Experimental Medicine and Biology (Schwarcz R. Ben-Ari Y., eds pp. 632 645. Plenum Press, New York.
31. Pangalos M. N., Schechter L. E. Hurko O. (2007) Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat. Rev. Drug Discov. 6, 521 532.
32. Paterson I. Anderson E. A. (2005) The renaissance of natural products as drug candidates. Science 310, 451 453.
33. Pezet S. Malcangio M. (2004) Brain-derived neurotrophic factor as a drug target for CNS disorders. Exp. Opin. Ther. Targets 8, 391 399.
34. Reinke A. A. Gestwicki J. E. (2007) Structure-activity relationships of amyloid beta-aggregation inhibitors based on curcumin: influence of linker length and flexibility. Chem Biol Drug Des. 70, 206 215.
35. Rice-Evans C. Miller N. J. (1994) Total antioxidant status in plasma and body fluids. Methods Enzymol. 234, 279 293.
36. Rice-Evans C. A., Miller N. J. Paganga G. (1996) Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic. Biol. Med. 20, 933 956.
37. Rossler O. G., Giehl K. M. Thiel G. (2004) Neuroprotection of immortalized hippocampal neurones by brain-derived neurotrophic factor and Raf-1 protein kinase: role of extracellular signal-regulated protein kinase and phosphatidylinositol 3-kinase. J. Neurochem. 88, 1240 1252.
38. Rothman S. M. (1985) The neurotoxicity of excitatory amino acids is produced by passive chloride influx. J. Neurosci. 5, 1483 1489.
39. Rothman S. M. Olney J. W. (1986) Glutamate and the pathophysiology of hypoxic - ischemic brain damage. Ann. Neurol. 19, 105 111.
40. Scatena R., Martorana G. E., Bottoni P., Botta G., Pastore P. Giardina B. (2007) An update on pharmacological approaches to neurodegenerative diseases. Exp. Opin. Invest. Drugs 16, 59 72.
41. Schubert D. R. Liu Y. (2002) Method for preventing and/or decreasing amyloid production with polycyclic compounds. US Patent No. 6,472,436B1.
42. Schubert D. Piasecki D. (2001) Oxidative glutamate toxicity can be a component of the excitotoxicity cascade. J. Neurosci. 21, 7455 7462.
43. Sharma R. A., Steward W. P. Gescher A. J. (2007) Pharmacokinetics and pharmacodynamics of curcumin. Adv. Exp. Med. Biol. 595, 453 470.
44. Sopher B. L., Fukuchi K., Smith A. C., Leppig K. A., Furlong C. E. Martin G. M. (1994) Cytotoxicity mediated by conditional expression of a carboxyl-terminal derivative of the beta-amyloid precursor protein. Brain Res. Mol. Brain Res. 26, 207 217.
45. Tan S., Schubert D. Maher P. (2001) Oxytosis: a novel form of programmed cell death. Curr. Topics Med. Chem. 1, 497 506.
46. Warren R. E. Frier B. M. (2005) Hypoglycaemia and cognitive function. Diabetes Obes Metab. 7, 493 503.
47. Woltjer R. L., Nghiem W., Maezawa I., Milatovic D., Vaisar T., Montine K. S. Montine T. J. (2005) Role of glutathione in intracellular amyloid-alpha precursor protein/carboxy-terminal fragment aggregation and associated cytotoxicity. J. Neurochem. 93, 1047 1056.
48. Yang F., Lim G. P., Begum A. N. et al. (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280, 5892 5901.
49. Yankner B. A., Duffy L. K. Kirschner D. A. (1990) Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 250, 279 282.